The Latest Humira Industry Statistics Explained
Humira is projected to be the second top-selling drug worldwide, with sales expected to be around $20 billion by 2026.
This statistic indicates that Humira, a popular medication used to treat various autoimmune diseases, is expected to generate significant sales and become the second highest-selling drug globally by 2026. The projected sales of around $20 billion demonstrate the high demand and market potential for this medication due to its effectiveness in managing chronic conditions such as rheumatoid arthritis and Crohn’s disease. The anticipated revenue reflects not only the increasing prevalence of autoimmune disorders but also the market dominance and success of Humira in meeting patients’ needs. As a result, Humira is poised to maintain its position as a top player in the pharmaceutical industry in the coming years.
In 2020, Humira was the best-selling drug in the United States with sales of $21.4 billion.
The statistic indicates that in the year 2020, Humira, a prescription medication used to treat various autoimmune conditions, was the top-selling drug in the United States with total sales amounting to $21.4 billion. This implies a significant demand and usage of Humira within the American market, likely driven by the prevalence of autoimmune diseases that require this specific medication for treatment. The sales figures highlight both the effectiveness and popularity of Humira among patients and healthcare providers, positioning it as a leading drug in terms of revenue generation within the pharmaceutical industry.
Humira’s sales performance helped make AbbVie the fourth highest earning pharmaceutical company in the world in 2018.
The statistic indicates that the sales performance of the drug Humira played a significant role in driving AbbVie to the fourth position among the highest-earning pharmaceutical companies globally in 2018. This implies that the revenue generated from Humira substantially contributed to AbbVie’s overall financial success for that year. Humira is a well-known and widely prescribed drug used to treat various autoimmune diseases, which has been a major revenue generator for AbbVie. The statistic highlights the importance of Humira’s sales in propelling AbbVie to a top position in the pharmaceutical industry in terms of earnings in 2018.
In the EU and the U.S., the exclusivity of Humira expired in 2018 leading to introduction of biosimilars.
The statistic indicates that in both the European Union (EU) and the United States, the exclusive patent protection for the drug Humira expired in 2018. This expiration allowed for the introduction of biosimilar versions of Humira, which are highly similar to the original drug in terms of quality, safety, and efficacy. Biosimilars offer a more affordable alternative to the branded version of Humira, providing patients with more options for treatment while potentially lowering healthcare costs. The expiration of exclusivity for Humira signifies a milestone in the pharmaceutical market, opening up competition and potentially increasing access to this widely used medication for conditions such as rheumatoid arthritis and other autoimmune diseases.
Among the biosimilar competitors to Humira, Amjevita, manufactured by Amgen, was the first to receive FDA approval in 2016.
The statistic states that among the various biosimilar competitors to the drug Humira, Amjevita, produced by the company Amgen, was the initial biosimilar to receive approval from the Food and Drug Administration (FDA) in the year 2016. This indicates that Amjevita was the first biosimilar version of Humira that met the necessary safety, efficacy, and quality standards required by the FDA for approval. Being the first approved biosimilar gives Amjevita a competitive advantage in the market as it can enter earlier and potentially gain a larger market share before other biosimilar competitors receive approval.
By 2026, it’s expected that 8 biosimilars of Humira will be on the market leading to increased competition.
This statistic suggests that the market for biosimilars of Humira, a popular biologic medication used to treat various conditions including rheumatoid arthritis, is expected to become more competitive by 2026. Biosimilars are highly similar versions of original biologic drugs, and having 8 biosimilars of Humira on the market implies a significant increase in options for patients and healthcare providers. This increased competition may lead to lower prices, improved access to treatment, and potentially more innovation in the field of biologics. Overall, the influx of biosimilars is anticipated to reshape the market dynamics for Humira and drive changes in the healthcare landscape.
It is estimated that Humira accounted for 63% of Abbvie’s total revenue in 2018.
This statistic indicates that Humira, a pharmaceutical drug produced by Abbvie, was a significant contributor to the company’s total revenue in 2018. Specifically, it is estimated that 63% of Abbvie’s total revenue for that year came from sales of Humira. This highlights the importance of Humira as a key product for Abbvie, showing that a large portion of the company’s financial success is dependent on the sales of this particular drug. The high percentage of revenue generated by Humira suggests its strong market presence and effectiveness in generating profits for Abbvie.
AbbVie spent approximately $4.7 billion in 2019 on marketing and promotion expenses, a lot of it on promoting Humira.
The statistic indicates that AbbVie, a pharmaceutical company, allocated a substantial amount of money, around $4.7 billion, towards marketing and promotion expenses in 2019, with a significant portion directed towards promoting their drug Humira. This highlights the company’s strategic focus on marketing efforts to create awareness and drive sales of their key product. Such a high level of spending underscores the competitive nature of the pharmaceutical industry, where companies invest heavily in marketing to differentiate their products and gain market share. The significant investment in promoting Humira also suggests its importance as a revenue-generating asset for AbbVie, emphasizing the company’s commitment to maximizing the drug’s market potential through robust marketing campaigns.
By 2023, Humira’s sales are expected to decrease by over half due to the emergence of competitors.
This statistic suggests that the sales of the drug Humira are projected to decline significantly by more than 50% by the year 2023. This decrease is attributed to the increasing competition in the pharmaceutical market as new competitors emerge with alternative drugs that could potentially replace or outperform Humira. The projected sales decline indicates a shift in market dynamics that may impact the market share and revenue of the drug manufacturer. It underscores the importance for the company to strategize and adapt to the changing landscape to maintain its competitive edge and financial performance in the face of evolving market conditions.
Humira’s revenue in the United States amounted to $13.7 billion in 2020.
The statistic ‘Humira’s revenue in the United States amounted to $13.7 billion in 2020’ indicates the total sales generated by the pharmaceutical product Humira in the US during that year. This figure reflects the significant economic impact of Humira in the market, highlighting its popularity and sales performance. The revenue can be used to assess the product’s market share, competitiveness, and overall contribution to the company’s financial performance. Additionally, this statistic provides insight into the demand for Humira and the potential profitability for the company that manufactures and sells this medication.
In 2019, Humira held over 85% of the global market share for TNF inhibitors, a class of drugs used in treating autoimmune diseases.
The statistic indicates that in 2019, Humira, a medication belonging to the class of TNF inhibitors used to treat autoimmune diseases, dominated the global market share by holding over 85% of it. This demonstrates the significant market presence and popularity of Humira compared to other similar drugs within the same therapeutic class. The high market share suggests that Humira is preferred by healthcare providers and patients due to factors such as efficacy, safety, accessibility, and brand recognition. This level of market dominance can have implications for pricing dynamics, competition, and overall pharmaceutical industry trends related to autoimmune disease treatment.
Humira’s peak sales year was in 2018, with global sales of $19.9 billion.
The statistic indicates that in 2018, Humira, a popular drug used to treat various autoimmune diseases, reached its highest level of sales, generating $19.9 billion in revenue globally. This peak sales year suggests a significant demand for Humira among healthcare providers and patients during that time. The substantial revenue generated in 2018 reflects the widespread use of Humira and highlights its effectiveness in treating conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. The success of Humira in 2018 may be attributed to factors such as positive clinical outcomes, effective marketing strategies, and a competitive market position in the pharmaceutical industry.
Approximately 500,000 Americans filled a prescription for Humira in 2019.
The statistic indicates that in the year 2019, around 500,000 individuals in the United States obtained a prescription for Humira, a medication commonly used to treat various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. This figure signifies the substantial number of Americans who are receiving treatment for these chronic conditions with the use of Humira. The statistic can also reflect the prevalence and impact of autoimmune diseases in the country, highlighting the demand for effective pharmaceutical interventions like Humira to manage these health conditions.
In Europe, Humira lost 80% of its market share within a year of biosimilar competition in 2019.
The statistic indicates that Humira, a popular biologic medication used to treat various inflammatory conditions, experienced a significant decrease in market share within the European market following the introduction of biosimilar competition in 2019. Specifically, the data shows that Humira’s market share dropped by 80% within just one year after facing competition from similar, lower-cost alternatives. This substantial loss in market share highlights the impact that biosimilar competition can have on the sales and dominance of a leading medication like Humira, signaling a shift in consumer and healthcare provider preferences towards more affordable treatment options in the region.
By 2022, global sales of Humira are projected to dip to $14.4 billion.
This statistic refers to the projected global sales of the drug Humira for the year 2022, which are expected to decrease to $14.4 billion from previous levels. Humira is a biologic medication used to treat various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis, among others. The anticipated decline in sales could be influenced by factors such as market competition from biosimilar versions of Humira, increased regulatory scrutiny, changes in healthcare policies, and shifts in prescribing patterns. Overall, this projection suggests a potential decrease in revenue generated from the sales of Humira in the global pharmaceutical market for the specified year.
As of 2022, six Humira biosimilars are approved by the European Medicines Agency.
The statistic indicates that as of 2022, the European Medicines Agency (EMA) has approved six biosimilars for Humira, a widely used biologic medication for treating various inflammatory conditions. Biosimilars are highly similar versions of original biologic drugs and are approved based on demonstrating comparable efficacy, safety, and quality. The approval of multiple biosimilars for Humira by the EMA provides healthcare providers and patients with increased treatment options, potentially leading to cost savings and improved access to this important medication. The availability of biosimilars can also enhance competition in the pharmaceutical market, promoting innovation and driving down prices for biologic therapies.
Total U.S. revenue from Humira was approximately $15.01 billion in 2021.
The statistic indicates that in 2021, the total revenue generated in the United States from sales of the medication Humira was approximately $15.01 billion. This revenue figure reflects the amount of money that Humira, a widely prescribed drug used to treat conditions such as rheumatoid arthritis and Crohn’s disease, brought in through sales within the U.S. market. The substantial revenue generated by Humira is indicative of its widespread use and effectiveness in treating various medical conditions, making it one of the top-selling prescription drugs in the country. This statistic is important for assessing the economic impact of Humira on the pharmaceutical industry and healthcare sector in the United States.
In 2020, the number of Medicare Part D beneficiaries using Humira was around 93,787.
In 2020, approximately 93,787 beneficiaries enrolled in Medicare Part D utilized Humira, a commonly prescribed medication typically used to treat conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. This statistic indicates the significant number of Medicare beneficiaries who require access to Humira for managing their health conditions and suggests a substantial demand for this specific medication within the Medicare population. The data highlights the importance of understanding the utilization patterns of expensive and critical medications like Humira among Medicare beneficiaries to ensure appropriate access and coverage for these essential treatments.
References
0. – https://www.investors.abbvie.com
1. – https://www.www.evaluate.com
2. – https://www.www.biopharmadive.com
3. – https://www.abbvie.gcs-web.com
4. – https://www.www.pharmaceutical-business-review.com
5. – https://www.www.pharmaceutical-technology.com
6. – https://www.www.ema.europa.eu
7. – https://www.www.forbes.com
8. – https://www.www.pharmacytimes.com
9. – https://www.www.statista.com
10. – https://www.seekingalpha.com
11. – https://www.www.robertscottbell.com
12. – https://www.www.biosimilardevelopment.com
13. – https://www.apnews.com
14. – https://www.www.fda.gov
